MichaelE.CoatsMD

PubMed

• 51 citations
  Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
  Robert M. Herndon, Richard A. Rudick, Frederick Munschauer, Michele Mass, Andres M. Salazar
  Multiple Sclerosis. 2005-08-01
• 21 citations
  Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials
  Donald E. Goodkin, Roger L. Priore, K. E. Wende, M. Campion, Dennis Bourdette
  Multiple Sclerosis. 1998-12-01
• 256 citations
  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
  Richard A. Rudick, N. A. Simonian, J. A. Alam, M. Campion, James Scaramucci
  Neurology. 1998-05-01

Journal Articles

• Longitudinal study of EEG and evoked potentials in neurologically asymptomatic HIV infected subjects.  
  Jabbari B, Coats M, Salazar AM, Martin A, Scherockman B, Law WA, EEG and Clinical Neurophysiology, 86:145-151
• A phase III trail of intramuscular recombinant interferon beta for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics ...  
  Jacobs LD, Cookfair DL, Rudick RA, Herdon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Emrich LJ, Bartoszak DM, Bourdette DN, Braiman J, B..., Multiple Sclerosis, 1:118-135
• Magnetic Resonance Studies of Intramuscular Interferon B-1a for Relapsing Multiple Sclerosis.  
  Simon JH, Jacobs LD, Campion MK, Wende K, Simonian NA, Cookfair DL, Rudick RA, Herdon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie..., Annals of Neurology; 43:79-87
• Eight year immunogenicity and safety of interferon beta Ia-Avonex treatment of patients with Multiple Sclerosis.  
  Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K, Mult Scler; 11(4):409-19
• Join now to see all

Abstracts/Posters

• Neurologic findings in early HIV infection.
  Coats M, Salazar AM, Martin A, Jabbari B, Geyer C, Burke D, and the Walter Reed Retrovirus Research Group, V International Conference on AIDS p459, Montreal
• Neurobehavioral studies in early HIV infection.
  Salazar AM, Martin A, Coats M, Williams J, Law W, Roller T, Graves M, Gomez C, IV Panamerican Symposium of Neuroepidemiology, Colombia
• Serial evoked potential studies in early human immune deficiency virus infection.
  Coats M, Jabbari B, Martin A, Salazar AM, American Academy of Neurology, Miami Beach, Florida
• Neurologic findings in early HIV infection: A prospective study.
  Coats M, Salazar AM, Martin A, Williams J, Brown D, Jabbari B, Brown H, Graves M, VI International Conference on AIDS #FB 367, 169, San Francisco, California
• Progressive slowing of reaction time and increasing levels of cerebrospinal fluid quinolinic acid in HIV + subjects.
  Martin A, Heyes MP, Salazar AM, Williams J, Law W, Roller T, Kampen D, Coats M, Markey SP, VI International conference on AIDS #FB 397, 177, San Francisco, California
• Progressive motor and cognitive slowing HIV + subjects: Possible relation to quinolinic acid.
  Martin A, Heyes MP, Salazar AM, Williams J, Law W, Roller T, Kampen D, Coats M, Markey SP, Neurological and Neuropsychological Complications of HIV Infection, Monterey, California
• Somatosensory evoked potentials in neurologically intact HIV infected subjects.
  Jabbari B, Coats M, Duncan M, Salazar AM, Martin A, European Congress of Neurophysiology, Paris
• Significance of Serum Neutralising Antibodies to Avonex (IFNB-1a) in Multiple Sclerosis.
  Rudick R, Jones W, Alam J, Simonian N, Campion M Jacobs L, Herndon R, Richert J, Salazar AM, Cookfair D, Simon J, Coats M, Goodkin D, Mass M, and the MSCRG, American Academy of Neurology, Boston
• Join now to see all